BioTime, Inc (BTX) Fair Value & Analysis
Other · Il · Market cap 512M ILA
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −4.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 2.32 ILA – 6.09 ILA · fair‑value band 1.54 ILA – 2.57 ILA · the 3.74 ILA price screens above the 2.06 ILA fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioTime, Inc (BTX) currently trades at 3.74 ILA, while our model-based Fair Value estimate is 2.06 ILA — implying the stock looks roughly 44.9% overvalued today. We read business quality at 86/100 (high quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
The stock trades on a trailing P/E of 3.5. Fundamentals as of Jun 24, 2026
About the company
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery …
Revenue & earnings trend
FY2014 – FY2018 · reported fiscal years
BioTime, Inc reported revenue of 5.0M ILA in FY2018 versus 5.2M ILA in FY2014, a compound −1.2%/yr. Reported net income was −46.0M ILA in FY2018.
Open the full interactive analysis →
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| GRFP GRFP | €6.43 | €2.58 | -60% |
| Stifel Financial Corporation SFB | $19.76 | $68.51 | +247% |
| EMBASSYRR EMBASSYRR | ₹428.99 | ₹124.62 | -71% |
Explore undervalued stocks
Frequently asked questions
Is BioTime, Inc (BTX) undervalued?
What is the fair value of BTX?
What is the quality score of BTX?
What is the net profit margin of BTX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.